LX-132

LX-132 is an orally bioavailable, potent, and selective small molecule inhibitor of the KRAS G12D mutant protein. Developed by Guangzhou Lixin Biotechnology, it is designed to target one of the most prevalent oncogenic mutations in human cancers, particularly in pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. By binding to the KRAS G12D protein, LX-132 inhibits the activation of the protein and its subsequent downstream signaling cascades, such as the RAF-MEK-ERK (MAPK) pathway, which are essential for tumor cell proliferation, survival, and metastasis. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced solid tumors harboring the KRAS G12D mutation.